First Tracks Biotherapeutics Inc TRAX 深 滬
交易中 10-29 10:12:26 美东时间
46.65
+0.930
+2.03%
華盛通- 最 高47.55
- 今 開46.18
- 成交量 3.75万股
- 最 低 45.586
- 昨 收 45.72
- 總市值 16.75亿
- 52周最高 49.9114
- 市盈率 靜 --
- 換手率 0.10%
- 52周最低 14.72
- 委 比 14.29%
- 總股本 3590.98万
- 歷史最高 49.9114
- 量 比 0.76
- 振 幅 4.30%
- 歷史最低 14.72
- 每 手 1
- 風險率 11.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | Bumble暴涨49.6%，传洽谈10亿美元私有化交易；Fair Isaac涨10.8%，裁员15%推进AI重组
Bumble暴涨49.6%，传洽谈10亿美元私有化交易；Fair Isaac涨10.8%，裁员15%推进AI重组
10-13 16:23
Why Is First Tracks Biotherapeutics Stock Soaring Monday?
First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX) on Monday released topline results from Cohort 1 of its Phase 1b clinical trial of ANB033 in celiac disease. Following the announcement, the stock jumped more than 13%. The clinical-stage biotechnology firm designed ANB033 as an investigational, subcu...
10-12 20:23
First Tracks Biotherapeutics' ANB033 Demonstrates Statistically Significant Histologic And Symptom Benefits In Phase 1b Celiac Disease Trial
ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms LS mean change from baseline in Vh:Cd ratio of -0.17 on ANB033 vs. -0.66 on placebo, a +0.49 placebo-adjusted delta (p=0.009) LS mean change from baseline in ...
10-12 19:04
美股夜盘 | First Tracks Biotherapeutics Inc暴升15.16%，最新股价36.68美元
First Tracks Biotherapeutics Inc暴升15.16%，报36.68美元
10-12 11:27
美股大行评级 | 潜在涨幅600.93%！Ascendiant Capital上调Aytu BioPharma目标价至15美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14.5美元升至15美元；摩根大通：维持Annexon"超配"评级，目标价从14美元升至15美元
10-01 19:18
Canaccord Genuity Initiates Coverage On First Tracks with Buy Rating, Announces Price Target of $50
Canaccord Genuity analyst Edward Nash initiates coverage on First Tracks (NASDAQ:TRAX) with a Buy rating and announces Price Target of $50.
09-30 19:36
美股大行评级 | 奈飞遭看淡至57美元！现价仍有两成下行空间；Xenon制药遭多家机构降目标价，最低看至46美元
今日重点评级关注：康托·菲茨杰拉德：维持Abeona Therapeutics"超配"评级，目标价从28美元升至30美元；HC Wainwright & Co.：维持Oculis Holding"买入"评级，目标价从26美元升至39美元
09-21 16:25
美股大行评级 | 矿业股获齐声唱多！金田、纽曼矿业等目标价均获上调；携程遭看淡至60美元，较现价仍溢价5成
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从10.25美元升至11美元；Needham：上调Rocket Pharmaceuticals"买入"评级，目标价9美元
09-17 16:16
Guggenheim Initiates Coverage On First Tracks with Buy Rating, Announces Price Target of $100
Guggenheim analyst Yatin Suneja initiates coverage on First Tracks (NASDAQ:TRAX) with a Buy rating and announces Price Target of $100.
09-16 20:12
